THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced that Neil K. Warma, the Company’s President and Chief Executive Officer, has been invited to present at the Cleveland Clinic’s 12th Annual Medical Innovation Summit, taking place October 26-29, 2014, in Cleveland, Ohio.
Opexa’s presentation is part of the Ground Waves showcase and will take place on Wednesday, October 29 at 9:15 am ET at the Cleveland Convention Center in Room 26.
Cleveland Clinic's 12th Annual Medical Innovation Summit will bring together more than 1,500 executives, investors, entrepreneurs and clinicians to examine the latest innovations in cancer treatment and personalized medicine. The Summit will feature a large variety of healthcare stakeholders from executives in pharmaceuticals, diagnostics and devices to information technology leaders, payers, investors, and entrepreneurs who will discuss the most promising market-ready therapies. The Summit, titled, "Now, it's Personal" will take a deep look at how targeted, personalized therapies are changing the game in medicine.
Ground Waves is a two-day showcase taking place as part of the Medical Innovation Summit that will present a wide array of companies making waves and looking to shake up the status quo in cancer treatment and personalized medicine.
About Opexa
Opexa is a biopharmaceutical company developing personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa’s proprietary T-cell technology. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. Tcelna is derived from T-cells isolated from the patient’s peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin. Opexa’s mission is to lead the field of Precision Immunotherapy® by aligning the interests of patients, employees and shareholders.
For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com.
